# OnCo record irae-haematological (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-haematological/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-haematological" ;
  schema:name "Blood side effects of checkpoint inhibitors: low platelets, haemolysis, neutropenia and marrow failure"@en ;
  schema:alternateName "haematological irAEs"@en, "hematologic immune-related adverse events"@en, "checkpoint inhibitor immune thrombocytopenia"@en, "ICI-related ITP"@en, "checkpoint inhibitor haemolytic anaemia"@en, "immune-related neutropenia"@en, "checkpoint inhibitor aplastic anaemia"@en, "ICI-related HLH"@en ;
  schema:description "Rarely, immunotherapy makes the immune system attack blood cells, causing low platelets (easy bruising or bleeding), destruction of red cells (tiredness, breathlessness, yellow skin, dark urine) or low white cells (infections). These are found on blood tests and treated with steroids and other medicines, usually with a haematologist involved."@en ;
  schema:url <https://onco.cc/protocols/irae-haematological/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "haematology" ;
  onco:related <https://onco.cc/protocols/irae-rechallenge/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/human-normal-immunoglobulin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/tocilizumab/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/thrombocytopenia/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .